Cost-effectiveness analysis of adjunct vsl#3 therapy versus standard medical therapy in pediatric ulcerative colitis

Journal of Pediatric Gastroenterology and Nutrition

Volumn 53, Issue 5, 2011, Pages 489-496

  Park, K T ^a   Perez, Felipe ^b   Tsai, Raymond ^b   Honkanen, Anita ^c   Bass, Dorsey ^a   Garber, Alan ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

Author keywords

Colectomy; Cost effectiveness analysis; Decision analysis; Ileal pouch anal anastamosis; Inflammatory bowel diseases; Quality of life; VSL 3

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MESALAZINE; VSL3;

ARTICLE; CHILDHOOD DISEASE; COLON RESECTION; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE ESCALATION; DRUG TREATMENT FAILURE; HEALTH STATUS; HOSPITAL COST; HUMAN; ILEITIS; ILEOANAL ANASTOMOSIS; ILEUM POUCH; MEDICAL CARE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CHILD; COLECTOMY; COLITIS, ULCERATIVE; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; MESALAMINE; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STANDARD OF CARE; TREATMENT OUTCOME;

EID: 80255139987     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3182293a5e     Document Type: Article

References (25)

1. Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17.
2. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007;5:1424-9. (Pubitemid 350181588)
3. Sewell JL, Yee HF Jr, Inadomi JM. Hospitalizations are increasing among minority patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2010;16:204-7.
4. Yu AP, Cabanilla LA, Wu EQ, et al. The costs of Crohn's disease in the United States and other Western countries: a systematic review. Curr Med Res Opin 2008;24:319-28. (Pubitemid 351294380)
5. Park KT, Bass D. Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review. Inflamm Bowel Dis 2010;17:1603-9.
6. Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. J Occup Environ Med 2008;50:1261-72.
7. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct healthcare costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 2008;135:1907-13.
8. Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009;104:437-43.
9. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a doubleblind, placebo-controlled trial. Gastroenterology 2000;119:305-9. (Pubitemid 30621980)
10. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108-14. (Pubitemid 38083018)
11. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind placebo controlled trial. Gastroenterology 2003;124:1202-9. (Pubitemid 36531796)
12. Gold MR, Siegel JE, Russell LB, eds. Cost-effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
13. Bureau of Economic Analysis, US Department of Commerce. Implicit price deflators for gross domestic product. http://www.bea.gov/national/nipaweb/ TableView.asp?SelectedTable=13&FirstYear=2005&Last Year=2007&Freq= Qtr. Published 2009. Accessed July 5, 2011.
14. Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009;104:437-43.
15. Chebli LA, Chaves LD, Pimentel FF, et al. Azathioprine maintains longterm steroid-free remission through 3 years in patients with steroiddependent ulcerative colitis. Inflamm Bowel Dis 2010;16:613-9.
16. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353:2462-76. (Pubitemid 41770166)
17. Ståhlberg D, Gullberg K, Liljeqvist L, et al. Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors. Dis Colon Rectum 1996;39:1012-8. (Pubitemid 26304984)
18. Söderlund S, Brandt L, Lapidus A, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009;136:1561-7.
19. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583-637.
20. Muir AJ, Edwards LJ, Sanders LL, et al. A prospective evaluation of health-related quality of life after ileal pouch anal anastomosis for ulcerative colitis. Am J Gastroenterol 2001;96:1480-5. (Pubitemid 32455078)
21. Provenzale D. Cost-effectiveness of screening the average-risk population for colorectal cancer. Gastrointest Endosc Clin N Am 2002;12:93-109. (Pubitemid 34072784)
22. National Vital Statistics Reports. United States life tables, 2001. http://www.cdc.gov/nchs/data/nvsr/nvsr52/nvsr52-14.pdf. Accessed July 5, 2011.
23. KornbluthA, SacharDB. Practice parametersCommittee of theAmerican College of Gastroenterology. Am J Gastroenterol 2004; 99:1371-85.
24. Fanjiang G, Russell GH, Katz AJ. Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 2007;44:312-7. (Pubitemid 46673377)
25. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423-32. (Pubitemid 47193130)